Tigecycline Clearance Basics
Tigecycline, a glycylcycline antibiotic, undergoes minimal renal clearance (about 15-20% unchanged). Most elimination occurs via biliary/fecal excretion (59%) and hepatic metabolism (33%), primarily through non-CYP pathways like glucuronidation and oxidative processes in the liver.[1][2]
How Liver Impairment Slows Clearance
In patients with moderate to severe hepatic impairment (Child-Pugh B or C), tigecycline's systemic clearance drops by 25-55% due to reduced hepatic metabolism and biliary excretion. Half-life extends from 27 hours (normal liver) to 53 hours (Child-Pugh C), leading to higher drug exposure (AUC increases up to 2-fold).[1][3]
- Child-Pugh A (mild): No dose adjustment needed; clearance near normal.
- Child-Pugh B (moderate): Start with 100 mg loading dose, then 25 mg every 12 hours (50% reduction).
- Child-Pugh C (severe): Same reduced dosing; monitor closely as data is limited.[2]
Clinical Dosing Adjustments
| Liver Function | Loading Dose | Maintenance Dose | Notes |
|---------------|--------------|------------------|-------|
| Normal (Child-Pugh A) | 100 mg | 50 mg q12h | Standard |
| Moderate (Child-Pugh B/C) | 100 mg | 25 mg q12h | Avoid in end-stage; clearance halved [1] |
No adjustment for renal impairment alone, but combined liver-kidney issues amplify risks.[2]
Risks of Unadjusted Dosing in Liver Disease
Elevated exposure raises nausea, vomiting, and hepatotoxicity risks. Steady-state concentrations can double without adjustment, potentially worsening liver function. Avoid in acute hepatic failure; use alternatives like non-hepatically cleared antibiotics.[3][4]
Monitoring and Alternatives
Check liver enzymes and bilirubin before/during therapy. Therapeutic drug monitoring isn't standard but helps in ICU settings. Alternatives for liver-impaired patients: meropenem or colistin for resistant infections, as they rely less on hepatic clearance.[4]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Tigecycline Pharmacokinetics
[3]: Clinical Pharmacology Review - Hepatic Impairment Study
[4]: IDSA Guidelines - Tigecycline Use